Ralliant Corporation (NYSE:RAL) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Ralliant Corporation (NYSE:RAL) have earned a consensus rating of “Moderate Buy” from the twelve ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $69.00.

Several research firms have weighed in on RAL. Oppenheimer increased their price objective on Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. TD Cowen boosted their target price on shares of Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, May 20th. Barclays upped their price target on shares of Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Citigroup raised their price target on shares of Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Finally, Evercore initiated coverage on shares of Ralliant in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price objective for the company.

Ralliant Stock Performance

Shares of NYSE RAL opened at $68.34 on Tuesday. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $7.65 billion and a P/E ratio of -6.25. Ralliant has a 12 month low of $37.27 and a 12 month high of $75.41. The stock has a 50 day moving average of $60.61 and a 200-day moving average of $51.93.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.49 by $0.08. The firm had revenue of $534.60 million for the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, equities research analysts predict that Ralliant will post 2.64 EPS for the current year.

Ralliant Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio is presently -1.83%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RAL. Danske Bank A S bought a new position in Ralliant in the 4th quarter valued at about $25,000. Allworth Financial LP raised its position in shares of Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares in the last quarter. V Square Quantitative Management LLC bought a new stake in shares of Ralliant during the 4th quarter worth approximately $26,000. Palisade Asset Management LLC bought a new stake in shares of Ralliant during the 3rd quarter worth approximately $26,000. Finally, Versant Capital Management Inc boosted its position in shares of Ralliant by 230.1% during the 2nd quarter. Versant Capital Management Inc now owns 604 shares of the company’s stock worth $44,000 after acquiring an additional 421 shares in the last quarter.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.